Acquired MET Exon 14 Skipping Mutation and Complex Mutations in EGFR-Mutated Lung Adenocarcinoma: A Case Report

We report an EGFR NSCLC patient with progression disease to Osimertinib due to METΔex14 mutation. As exon 21 L858R substitution was still detected, the patient was treated with the combination of Osimertinib and Capmatinib. After 3 months, radiological progression disease and C797S and V802F as new on target mutations were detected, so Gefitinib was administered in monotherapy, with patient exitus due to neumothorax secondary to massive cavitation of his lung cancer 3 months later.